• Forte Biosciences posted a net loss of USD 22.14 million, or USD 1.24 per share, versus a net loss of USD 15.66 million, or USD 1.37 per share, a year earlier.
• Research and development expense climbed to USD 20.5 million from USD 12.7 million, while general and administrative expense fell to USD 2 million from USD 3.4 million.
• Cash and cash equivalents totaled USD 58.22 million at March 31, down from USD 76.96 million at Dec. 31.
• FB102 received FDA Fast Track designation in celiac disease, with phase 2 celiac topline results expected in 2026.
• Management said FB102 phase 1b vitiligo topline results are expected shortly, while phase 1b alopecia areata data are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605110901BIZWIRE_USPR_____20260511_BW177742) on May 11, 2026, and is solely responsible for the information contained therein.